Physician profile
Brian Hunt Thomas
NPI 1649309329
$15,020.69
in general payments reported to CMS, 2019-2025
33 companies · $2,826 in 2025
The $2,826 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,143 · 2020: $479 · 2021: $2,062 · 2022: $1,976 · 2023: $2,938 · 2024: $3,597 · 2025: $2,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,361.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,883.03 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $1,184.89 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,170.14 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,011.64 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $974.10 | 2021-2025 | Vraylar |
| Lundbeck LLC | $925.77 | 2019-2025 | Rexulti |
| Corium, LLC | $780.47 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $766.61 | 2019-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $674.17 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $669.04 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $633.80 | 2019-2024 | Jornay Pm |
| Bausch Health US, LLC | $517.98 | 2019-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $392.07 | 2019-2025 | Ingrezza |
| Alfasigma USA, INC. | $315.15 | 2020-2022 | |
| Noven Therapeutics, LLC | $306.52 | 2023-2025 | Xelstrym, Secuado |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $283.97 | 2022-2025 | Austedo Xr, Austedo Xr |
| Neos Therapeutics, LP | $256.05 | 2019-2023 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $237.63 | 2019-2025 | Fanapt, Hetlioz |
| Collegium Pharmaceutical, INC. | $193.47 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $183.33 | 2022-2024 | Quviviq |
| Shire North American Group INC | $119.57 | 2019 | |
| Adlon Therapeutics L.P. | $115.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $95.70 | 2022-2023 | Belsomra |
| Eisai INC. | $60.52 | 2020-2021 | |
| Brainsway USA INC | $48.54 | 2023-2024 | Brainsway Deep Tms System |
| Jazz Pharmaceuticals INC. | $44.84 | 2021 | |
| Noven Pharmaceuticals, INC. | $36.80 | 2023-2024 | Xelstrym |
| Arbor Pharmaceuticals, INC. | $30.67 | 2019 | |
| Allergan, INC. | $26.27 | 2019-2020 | |
| Alkermes, INC. | $24.52 | 2025 | Aristada, Lybalvi |
| Tempus Ai, INC | $24.04 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $20.88 | 2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.